MARKET

KAPA

KAPA

KAIROS PHARMA LTD
AMEX
0.6000
-0.0308
-4.88%
After Hours: 0.6001 +0.0001 +0.02% 19:15 03/12 EDT
OPEN
0.6356
PREV CLOSE
0.6308
HIGH
0.6409
LOW
0.5900
VOLUME
136.99K
TURNOVER
--
52 WEEK HIGH
2.110
52 WEEK LOW
0.4000
MARKET CAP
12.49M
P/E (TTM)
-1.9704
1D
5D
1M
3M
1Y
5Y
1D
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
TipRanks · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Pfizer (PFE) and Medtronic (MDT)
TipRanks · 1d ago
Weekly Report: what happened at KAPA last week (0302-0306)?
Weekly Report · 3d ago
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
TipRanks · 03/02 12:19
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
TipRanks · 03/02 11:53
Kairos Pharma Enters Into Binding Terms To Acquire CL-273 From Celyn Therapeutics For Undisclosed Sum; Transaction Is Expected To Be Value‑Accretive
Benzinga · 03/02 11:32
Weekly Report: what happened at KAPA last week (0223-0227)?
Weekly Report · 03/02 10:12
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Barchart · 03/02 05:30
More
About KAPA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.

Webull offers Kairos Pharma Ltd stock information, including AMEX: KAPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KAPA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KAPA stock methods without spending real money on the virtual paper trading platform.